NasdaqGM - Delayed Quote • USD
Iovance Biotherapeutics, Inc. (IOVA)
At close: May 17 at 4:00 PM EDT
After hours: May 17 at 7:49 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 12 | 12 | 10 | 10 |
| Avg. Estimate | -0.34 | -0.29 | -1.34 | -0.72 |
| Low Estimate | -0.44 | -0.45 | -1.79 | -1.52 |
| High Estimate | -0.29 | -0.14 | -1 | -0.01 |
| Year Ago EPS | -0.47 | -0.46 | -1.89 | -1.34 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 12 | 12 | 12 | 11 |
| Avg. Estimate | 29.29M | 54.99M | 161.19M | 442.21M |
| Low Estimate | 5.2M | 11.2M | 33.2M | 130.5M |
| High Estimate | 56.77M | 85M | 248.7M | 620.34M |
| Year Ago Sales | 238k | 469k | 1.19M | 161.19M |
| Sales Growth (year/est) | 12,206.70% | 11,624.90% | 13,456.80% | 174.30% |
Earnings History
| CURRENCY IN USD | 6/30/2023 | 9/30/2023 | 12/31/2023 | 3/31/2024 |
|---|---|---|---|---|
| EPS Est. | -0.8 | -0.45 | -0.43 | -0.42 |
| EPS Actual | -0.47 | -0.46 | -0.45 | -0.42 |
| Difference | 0.33 | -0.01 | -0.02 | 0 |
| Surprise % | 41.30% | -2.20% | -4.70% | 0.00% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.34 | -0.29 | -1.34 | -0.72 |
| 7 Days Ago | -0.35 | -0.28 | -1.27 | -0.71 |
| 30 Days Ago | -0.36 | -0.29 | -1.29 | -0.71 |
| 60 Days Ago | -0.36 | -0.29 | -1.29 | -0.71 |
| 90 Days Ago | -0.37 | -0.32 | -1.36 | -0.94 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 7 | 6 | 5 | 4 |
| Up Last 30 Days | 8 | 7 | 7 | 7 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | 3 | 4 | 4 | 3 |
Growth Estimates
| CURRENCY IN USD | IOVA | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 27.70% | -- | -- | 8.00% |
| Next Qtr. | 37.00% | -- | -- | 12.40% |
| Current Year | 29.10% | -- | -- | 5.60% |
| Next Year | 46.30% | -- | -- | 13.00% |
| Next 5 Years (per annum) | -19.00% | -- | -- | 11.14% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 5/10/2024 |
| Maintains | Piper Sandler: Overweight to Overweight | 3/14/2024 |
| Maintains | Truist Securities: Buy to Buy | 3/7/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 3/4/2024 |
| Maintains | Wells Fargo: Overweight to Overweight | 3/1/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 2/29/2024 |
Related Tickers
IBRX ImmunityBio, Inc.
7.65
-1.29%
VKTX Viking Therapeutics, Inc.
67.00
-2.98%
TGTX TG Therapeutics, Inc.
16.48
-5.40%
ALT Altimmune, Inc.
8.01
-10.00%
AXSM Axsome Therapeutics, Inc.
76.54
-1.05%
MDGL Madrigal Pharmaceuticals, Inc.
220.06
+1.33%
CYTK Cytokinetics, Incorporated
59.53
-0.65%
SAVA Cassava Sciences, Inc.
23.12
+7.24%
BHVN Biohaven Ltd.
37.37
-2.81%
ARQT Arcutis Biotherapeutics, Inc.
9.20
+0.88%